Text Size

A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Andrea Doolan, University College Cork
ClinicalTrials.gov Identifier:
NCT01321281
First received: March 22, 2011
Last updated: May 14, 2012
Last verified: May 2012
History of Changes
  Purpose

Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45.

This study aim to determine if Aquamin (as AquaCal and AquaPT) affects molecules of inflammation in the blood of osteoarthritis and healthy subjects.


Condition Intervention Phase
Osteoarthritis
 Dietary Supplement: AquaCal
Dietary Supplement: AquaPT
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Supportive Care
Official Title: Randomised, Placebo Controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects

Resource links provided by NLM:

MedlinePlus related topics: Osteoarthritis
U.S. FDA Resources

Further study details as provided by University College Cork:

Primary Outcome Measures:
  • Cytokines [ Time Frame: Baseline (wk 0) & wk 6 ] [ Designated as safety issue: No ]
    Plasma cytokine concentrations (including TNFα, IL-β, NFκB, COX2 & IL-6)


Secondary Outcome Measures:
  • WOMAC Questionnaire [ Time Frame: Wk0 & Wk6 ] [ Designated as safety issue: No ]
    Western Ontario and McMaster Universities Arthritis Index

  • Full Blood Count [ Time Frame: Wk0 & Wk6 ] [ Designated as safety issue: Yes ]
    Haemaglobin, white cell count, platelet count, haematocrit, differential white count

  • Chemistry Profile [ Time Frame: Wk0 & Wk6 ] [ Designated as safety issue: Yes ]
    Including Sodium, Potassium, Chloride, Urea, Creatinine, Protein, Albumin


Enrollment: 36
Study Start Date: March 2011
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AquaCal
Osteoarthritis and healthy volunteers
 Dietary Supplement: AquaCal

AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.

The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
Active Comparator: AquaPT
Osteoarthritis
 Dietary Supplement: AquaPT

AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.

The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

To be considered eligible for enrollment into the study, subjects must;

  • Be able to give written informed consent.
  • Be female and between 18 and 65 years of age.
  • Be a non-pregnant female.
  • Be in generally good health as determined by the investigator.
  • Osteoarthritis patients must have a clinical diagnosis of moderate to severe osteoarthritis.

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the below criteria;

  • Are less than 18 and greater than 65 years of age.
  • Are pregnant females.
  • Are currently taking probiotics or vitamin supplements, or have taken them in the past 14 days.
  • Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgment, entry to the study).
  • Having a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include non-steroidal anti-inflammatory drugs (NSAIDs), steroids and vitamin.
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
  • Subjects may not be receiving treatment involving experimental drugs.
  • If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
  • Have a malignant disease or any concomitant end-stage organ disease.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01321281

Locations
Ireland
Cork University Hospital
Cork, Ireland
Sponsors and Collaborators
Andrea Doolan
Investigators
Principal Investigator: Timothy Dinan University College Cork
  More Information

No publications provided

Responsible Party: Andrea Doolan, Human Studies Manager, University College Cork
ClinicalTrials.gov Identifier: NCT01321281     History of Changes
Other Study ID Numbers: APC026-Marigot
Study First Received: March 22, 2011
Last Updated: May 14, 2012
Health Authority: Ireland: Research Ethics Committee

Keywords provided by University College Cork:
Osteoarthritis

Additional relevant MeSH terms:
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on May 22, 2013